Moleculin Reports Q2 Loss, Cash Runway Into Q1 2027, and MIRACLE Trial Milestones
MBRX has more than doubled off its 52-week low of $0.161.
Summary
Moleculin reported Q2 2026 financials with a $7.6M net loss and cash runway into Q1 2027, while confirming MIRACLE trial milestones including a 90-patient enrollment target in September and unblinded data readout in December 2026 to February 2027.
Key Events · Earnings and Guidance · MBRX
-
Q2 2026 Financial Results
Net loss of $7.6M for Q2 2026, with R&D expenses up $1.9M to $5.5M driven by the MIRACLE trial. Cash and equivalents were $7.3M as of June 30, 2026.
-
Cash Runway Extended
Management expects cash on hand plus $9.3M raised after quarter-end to fund operations into Q1 2027, providing near-term liquidity despite going-concern doubts.
-
MIRACLE Trial Milestones
Enrollment completion in Part A expected September 2026, unblinded efficacy readout December 2026 to February 2027, and Part B initiation in 1H 2027.
-
Interim Efficacy Reaffirmed
Positive interim data showed CR rates of 43% and 36% in Annamycin arms vs 12% control, with no cardiotoxicity observed.
Analysis · MBRX · Life Sciences
Moleculin's Q2 results show a $7.6M net loss and $7.3M cash on hand, but the $9.3M raised after quarter-end extends the runway into Q1 2027. The company reiterated positive interim MIRACLE data and set concrete milestones: 90-patient enrollment by September 2026, unblinded readout December 2026 to February 2027, and Part B initiation in 1H 2027. For a micro-cap with going-concern doubts and Nasdaq delisting risk, this update provides critical visibility into both the clinical timeline and the cash runway.
At the time of this filing, MBRX was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.16 to $17.38. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.